Literature DB >> 20709903

Efficient osteoclast differentiation requires local complement activation.

Zhidan Tu1, Hong Bu, James E Dennis, Feng Lin.   

Abstract

Previous studies using blocking antibodies suggested that bone marrow (BM)-derived C3 is required for efficient osteoclast (OC) differentiation, and that C3 receptors are involved in this process. However, the detailed underlying mechanism and the possible involvement of other complement receptors remain unclear. In this report, we found that C3(-/-) BM cells exhibited lower RANKL/OPG expression ratios, produced smaller amounts of macrophage colony-stimulating factor and interleukin-6 (IL-6), and generated significantly fewer OCs than wild-type (WT) BM cells. During differentiation, in addition to C3, WT BM cells locally produced all other complement components required to activate C3 and to generate C3a/C5a through the alter-native pathway, which is required for efficient OC differentiation. Abrogating C3aR/C5aR activity either genetically or pharmaceutically suppressed OC generation, while stimulating WT or C3(-/-) BM cells with exogenous C3a and/or C5a augmented OC differentiation. Furthermore, supplementation with IL-6 rescued OC generation from C3(-/-) BM cells, and neutralizing antibodies to IL-6 abolished the stimulatory effects of C3a/C5a on OC differentiation. These data indicate that during OC differentiation, BM cells locally produce components, which are activated through the alternative pathway to regulate OC differentiation. In addition to C3 receptors, C3aR/C5aR also regulate OC differentiation, at least in part, by modulating local IL-6 production.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709903      PMCID: PMC2996112          DOI: 10.1182/blood-2010-01-263590

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis.

Authors:  Max Albert Hietala; Kutty S Nandakumar; Linda Persson; Susann Fahlén; Rikard Holmdahl; Marcela Pekna
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

2.  Interaction of triiodothyronine with 1alpha,25-dihydroxyvitamin D3 on interleukin-6-dependent osteoclast-like cell formation in mouse bone marrow cell cultures.

Authors:  C Schiller; R Gruber; G M Ho; K Redlich; H J Gober; F Katzgraber; M Willheim; O Hoffmann; P Pietschmann; M Peterlik
Journal:  Bone       Date:  1998-04       Impact factor: 4.398

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3.

Authors:  B L Myones; J G Dalzell; N Hogg; G D Ross
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

5.  Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Authors:  N Udagawa; N Takahashi; E Jimi; K Matsuzaki; T Tsurukai; K Itoh; N Nakagawa; H Yasuda; M Goto; E Tsuda; K Higashio; M T Gillespie; T J Martin; T Suda
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

6.  The specific production of the third component of complement by osteoblastic cells treated with 1 alpha,25-dihydroxyvitamin D3.

Authors:  T Sato; M H Hong; C H Jin; Y Ishimi; N Udagawa; T Shinki; E Abe; T Suda
Journal:  FEBS Lett       Date:  1991-07-08       Impact factor: 4.124

7.  Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells.

Authors:  N Takahashi; N Udagawa; T Akatsu; H Tanaka; Y Isogai; T Suda
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

8.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

9.  A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.

Authors:  Hongbin Song; Fei Qiao; Carl Atkinson; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

Review 10.  Allograft rejection: effect of local synthesis of complement.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Springer Semin Immunopathol       Date:  2005-11-11
View more
  29 in total

Review 1.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

2.  Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

Authors:  Lingjun Zhang; Wen Qiu; Stephen Crooke; Yan Li; Areeba Abid; Bin Xu; M G Finn; Feng Lin
Journal:  ACS Chem Biol       Date:  2017-01-12       Impact factor: 5.100

3.  Reduced bone loss in a murine model of postmenopausal osteoporosis lacking complement component 3.

Authors:  Danielle L MacKay; Thomas J Kean; Kristina G Bernardi; Heather S Haeberle; Catherine G Ambrose; Feng Lin; James E Dennis
Journal:  J Orthop Res       Date:  2017-07-25       Impact factor: 3.494

Review 4.  Bone and the innate immune system.

Authors:  Julia F Charles; Mary C Nakamura
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

5.  Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss.

Authors:  Wei Yu; Leilei Zhong; Lutian Yao; Yulong Wei; Tao Gui; Ziqing Li; Hyunsoo Kim; Nicholas Holdreith; Xi Jiang; Wei Tong; Nathaniel Dyment; X Sherry Liu; Shuying Yang; Yongwon Choi; Jaimo Ahn; Ling Qin
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

6.  Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Authors:  Leticia Corrales; Daniel Ajona; Stavros Rafail; Juan J Lasarte; Jose I Riezu-Boj; John D Lambris; Ana Rouzaut; Maria J Pajares; Luis M Montuenga; Ruben Pio
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

7.  C5aR-antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing.

Authors:  Stefan Recknagel; Ronny Bindl; Julian Kurz; Tim Wehner; Philipp Schoengraf; Christian Ehrnthaller; Hongchang Qu; Florian Gebhard; Markus Huber-Lang; John D Lambris; Lutz Claes; Anita Ignatius
Journal:  J Orthop Res       Date:  2011-09-15       Impact factor: 3.494

8.  The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells.

Authors:  Ching-Chuan Hsieh; Hong-Shiue Chou; Horng-Ren Yang; Feng Lin; Sumantha Bhatt; Jie Qin; Lianfu Wang; John J Fung; Shiguang Qian; Lina Lu
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

9.  Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.

Authors:  Jason J Song; Inyong Hwang; Kyung H Cho; Michael A Garcia; Arthur J Kim; Tiffany H Wang; Tamsin M Lindstrom; Annette T Lee; Toshihiko Nishimura; Lei Zhao; John Morser; Michael Nesheim; Stuart B Goodman; David M Lee; S Louis Bridges; Peter K Gregersen; Lawrence L Leung; William H Robinson
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

Review 10.  Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis.

Authors:  Dimitrios C Mastellos; Robert A Deangelis; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-17       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.